These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions. Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299 [TBL] [Abstract][Full Text] [Related]
5. IMP-3 is a novel progression marker in malignant melanoma. Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432 [TBL] [Abstract][Full Text] [Related]
7. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Kapur P; Selim MA; Roy LC; Yegappan M; Weinberg AG; Hoang MP Mod Pathol; 2005 Feb; 18(2):197-204. PubMed ID: 15467715 [TBL] [Abstract][Full Text] [Related]
8. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543 [TBL] [Abstract][Full Text] [Related]
9. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms. McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825 [TBL] [Abstract][Full Text] [Related]
10. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Nasr MR; El-Zammar O Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113 [TBL] [Abstract][Full Text] [Related]
11. Expression of polycomb group protein EZH2 in nevi and melanoma. McHugh JB; Fullen DR; Ma L; Kleer CG; Su LD J Cutan Pathol; 2007 Aug; 34(8):597-600. PubMed ID: 17640228 [TBL] [Abstract][Full Text] [Related]
12. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132 [TBL] [Abstract][Full Text] [Related]
13. Expression of cyclins A and E in melanocytic skin lesions and its correlation with some clinicopathologic features. Alekseenko A; Wojas-Pelc A; Lis GJ; Wiśniowski Z; Czerwińska M; Niewiara Ł; Litwin JA Folia Histochem Cytobiol; 2012 Jul; 50(2):263-9. PubMed ID: 22763964 [TBL] [Abstract][Full Text] [Related]
14. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545 [TBL] [Abstract][Full Text] [Related]
15. Expression of p-27 (kip1) in nevi and melanomas. Morgan MB; Cowper SE Am J Dermatopathol; 1999 Apr; 21(2):121-4. PubMed ID: 10218670 [TBL] [Abstract][Full Text] [Related]
18. Progression-related expression of beta3 integrin in melanomas and nevi. Van Belle PA; Elenitsas R; Satyamoorthy K; Wolfe JT; Guerry D; Schuchter L; Van Belle TJ; Albelda S; Tahin P; Herlyn M; Elder DE Hum Pathol; 1999 May; 30(5):562-7. PubMed ID: 10333228 [TBL] [Abstract][Full Text] [Related]
19. S100A6 protein expression is different in Spitz nevi and melanomas. Ribé A; McNutt NS Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257 [TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 expression in melanocytic lesions of the skin. Ramirez JA; Guitart J; Rao MS; Diaz LK Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]